Category Archives: oud

You’ll Never Guess The Top-Performing Income Strategies Of 2016

There’s been a lot of drama surrounding financial markets during the first four months of 2016. By some measures, it was the worst start to the year ever for U.S. stocks. This was followed by a surprisingly robust recovery. But for all the painful turmoil, the S&P 500 is trading pretty much where it started the year. This flat performance also means many income strategies are outperforming stocks by a wide margin in 2016. Of course, income investments come in all shapes and sizes. You can invest in high-dividend stocks (both domestic and international), high-yield bonds, Real Estate Investment Trusts (REITs), Business Development Companies (BDCs), Master Limited Partnerships (MLPs) or even strategies that generate income by selling call options against the S&P 500. Over the long term, a mixture of these strategies is most prudent. After all, every strategy has its day. What works today won’t necessarily work tomorrow. Just ask any investor in MLPs, which have been hit unusually hard by the collapse of the energy sector. Looking across today’s landscape of income investments, there’s a new, hot sector in income-generating strategies. And I bet it’s one that you have not looked at in years. As I surveyed the top-performing, income-oriented investments for 2016, I was surprised to find that it was the much-derided international stock markets – or more specifically, emerging markets – that accounted for three out of the five top-performing income investment strategies that I track. The top-performing strategy invested in REITs, but it did so across the globe. With that, here are the… Top Performing Income ETFs in 2016 Global X Super Dividend REIT ETF (NASDAQ: SRET ) – 15.72% Gain The Global X SuperDividend REIT ETF invests in 30 of the highest dividend-yielding REITs globally. SRET invests in REITs from around the globe, which diversifies both geographic and interest rate exposure. Global REITs are having their day in the sun because housing shortages – exacerbated by lagging construction after the 2008 financial crisis – have combined with a recovering economy to boost demand for real estate. SRET yields a whopping 9.09% yield. SRET makes distributions on a monthly basis, providing a regular source of income for a portfolio. The fund’s total expense ratio is 0.58%. SRET has risen 12.34% so far this year. With dividends, SRET has generated a total return of 15.72% year to date. A word of warning: The total assets of this REIT are a mere $5.6 million, so you may run into wide bid-ask spreads or even liquidity issues with this one. ALPS Emerging Sector Dividend Dogs ETF (NYSEARCA: EDOG ) – 14.19% Gain The ALPS Emerging Sector Dividend Dogs ETF tracks a proprietary index comprised of the 500 largest stocks from middle-income emerging market countries. It then invests in the five highest-yielding securities (based on regular cash dividends) in each of the 10 Global Industry Classification Standard (GICS) sectors. EDOG yields 3.79%, and makes distributions on a quarterly basis. The fund’s total expense ratio is 0.60%. EDOG has risen 13.58% so far this year. With dividends, it has generated a total return of 14.19% year to date. Pimco Municipal Income Fund II (NYSE: PML ) – 12.29% Gain The PIMCO Municipal Income Fund II is an actively managed, highly leveraged municipal fund. The fund typically generates its large distribution by venturing down the credit spectrum into non-rated and junk-rated muni debt, focusing on the intermediate and long portions of the yield curve, then leveraging its holdings. Say the words “invest in municipal bonds,” and most investors can barely stifle a yawn. Yet, returns on municipal bonds have beaten the broader stock market in 2015 and are among the best-performing income investments over the past five years. That’s a surprise. After all, in 2012, major cities in the United States such as Detroit and San Bernardino, California, went bankrupt. Analyst Meredith Whitney grabbed headlines with her prediction that there would be between 50 and 100 “significant” municipal bond defaults in 2011, totaling “hundreds of billions” of dollars. Very little of this doom and gloom came to pass. PML yields 6.12%. PML has maintained a level income-only monthly distribution of $0.065 per share since 2007. PML has logged returns of an annualized 13.46% over the past five years. The fund’s total expense ratio is a relatively high 1.16%. PML has risen 9.99% so far this year and, with dividends, it has generated a total return of 12.29% year to date. EGShares Low Volatility Emerging Markets Dividend ETF (NYSEARCA: HILO ) – 9.49% Gain The EGShares Low Volatility Emerging Markets Dividend ETF tracks the EGAI Emerging Markets Quality Dividend Index. This is an equal-weighted index designed to represent a portfolio of approximately 50 companies in developing markets, each of which has a higher dividend yield than the average dividend yield in the EGAI Developing Markets Universe. The fund also seeks to capture dividend quality by screening for factors such as return on equity, positive earnings growth, maximum dividend yield and three-year dividend payment consistency. HILO yields 2.89%. HILO makes distributions on a quarterly basis. The fund’s total expense ratio is a relatively high 0.85%. HILO has risen 8.72% so far this year and, with dividends, it has generated a total return of 9.49% year to date. Global X SuperDividend Emerging Markets ETF (NYSEARCA: SDEM ) – 9.12% Gain The Global X SuperDividend Emerging Markets ETF invests in 50 of the highest dividend-yielding equities in emerging markets. Investing in high dividend-yielding securities in the emerging market space combines a value-oriented investment approach with exposure to markets that are expected to grow at a faster pace than developed markets. SDEM yields 6.89%. SDEM makes distributions on a monthly basis, providing a regular source of income for a portfolio. The fund’s total expense ratio is 0.65%. SDEM has risen 6.92% so far this year. With dividends, it has generated a total return of 9.12% year to date.

Jazz Pharma Rises As Competitive Position Grows Stronger

Specialty drugmaker Jazz Pharmaceuticals ( JAZZ ) was trading up Wednesday morning as its lead drug staved off competition until the end of 2025, even though the company missed Q1 estimates late Tuesday. Jazz has been embroiled in litigation over its narcolepsy treatment Xyrem, as seven different generic-drug makers have been challenging its aging patents. On Tuesday’s earnings conference call with analysts, CEO Bruce Cozadd said that Jazz had reached a confidential settlement with two of them, Ranbaxy and Wockhardt Bio, which would allow them to start selling generic Xyrem, but not until Dec. 31, 2025. The news led Mizuho Securities analyst Irina Koffler to upgrade Jazz Pharma stock to buy from neutral, and raise the price target to 193 from 137. “Jazz’s announcement of its late 2025 Xyrem settlements was the upgrade signal we were looking for,” Koffler wrote in a research note. Bargaining From Strength Leerink analyst Jason Gerberry raised his price target to 198 from 137 while maintaining an outperform rating. He wrote that the patent launch was a year later than he’d been modeling, and came after last month’s favorable decision from the patent office declining to institute 18 claims Ranbaxy made against Jazz’s Xyrem patent, meaning that Ranbaxy would have to take Jazz to open court instead of banking on an inter partes review (IPR) ruling set for July. “Given favorable first-half developments in the IPR dispute … we believe Jazz is well positioned to entice the other challengers to accept similar settlement terms, eliminating an important stock overhang,” Gerberry wrote in his research note. The news lifted Jazz Pharma stock as much as 5.5% in early trading on the stock market today , though by midday shares were up just 1.5%, near 150, as Jazz reported a weak first quarter. Jazz’s earnings rose 14% over the year-earlier quarter to $2.26 a share, 5 cents short of analysts’ consensus, according to Thomson Reuters. Revenue climbed 9% to $336 million, missing consensus by almost $3 million. Jazz nonetheless added 20 cents to its 2016 EPS range, now $11.10 to $11.50, while affirmed revenue guidance of $1.49 billion to $1.55 billion. The earnings hike came entirely through share repurchases. Last year, the company made $9.52 a share on $1.325 billion in sales.